GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Beta

ObsEva (ObsEva) Beta : -0.24 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ObsEva Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-05), ObsEva's Beta is -0.24.


ObsEva Beta Historical Data

The historical data trend for ObsEva's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Beta Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beta
Get a 7-Day Free Trial Premium Member Only - 0.50 0.89 0.51 0.57

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.69 0.62 0.26 0.57

Competitive Comparison of ObsEva's Beta

For the Biotechnology subindustry, ObsEva's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Beta distribution charts can be found below:

* The bar in red indicates where ObsEva's Beta falls into.



ObsEva Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


ObsEva  (GREY:OBSEF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


ObsEva Beta Related Terms

Thank you for viewing the detailed overview of ObsEva's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228